EUVIMEDEUVIMED entdecken
Open Access

TGFβR1 inhibition drives hepatocellular carcinoma proliferation through induction of toll‐like‐receptor signalling

Fatma El Zahraa Ammar Mohamed iD, Bedair Dewidar, Tao Lin, Matthias P Ebert, Steven Dooley, Nadja M Meindl-Beinker, Seddik Hammad

International Journal of Experimental Pathology · 2024

DOI: 10.1111/iep.12501 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Experimental Pathology, 2024. Verfasst von Fatma El Zahraa Ammar Mohamed und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Faculty of Medicine, Minia University, Minia, Egypt. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carcinoma, Hepatocellular, Cytostatic Agents, Liver Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: German Federal Ministry of Education and Research, Alexander von Humboldt-Stiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Transforming growth factor (TGF)‐β and toll‐like receptors (TLRs) have been shown to independently modulate the proliferation of hepatocellular carcinoma (HCC). Since a direct cross‐talk between these two signalling pathways in HCC has not been clearly described before, we aimed here to explore the possibility of such interaction. A human HCC tissue array ( n = 20 vs. four control samples), human HCC samples ( n = 10) and steatohepatitis‐driven murine HCC samples (control, NASH and HCC; n = 6/group) were immunostained for TGFβR1, pSMAD2, TRAF6, IRAK1 and PCNA. The results were confirmed by immunoblotting. Effects of constant activation of the SMAD pathway by constitutive expression of ALK5 or knockdown of mediators of TLR signalling, IRAK1 and MyD88, on HCC proliferation, were investigated in the HCC cell line (HUH‐7) after treatment with TGFβ1 cytokine or TGFβR1 kinase inhibitor (LY2157299) using PCNA and MTS assay. TGFβR1 expression is decreased in human and murine HCC and associated with downregulated pSMAD2, but increased IRAK1, TRAF6 and PCNA staining. TGFβR1 kinase inhibition abolished the cytostatic effects of TGFβ1 and led to the induction of IRAK1, pIRAK1 and elevated mRNA levels of TLR‐9. Overexpression of ALK5 and knockdown of MyD88 or IRAK1 augmented the cytostatic effects of TGFβ1 on HUH‐7. In another epithelial HCC cell line, that is, HepG2, TGFβR1 kinase inhibitor similarly elevated cellular proliferation. There is a balance between the canonical SMAD‐driven tumour‐suppressing arm and the non‐canonical tumour‐promoting arm of TGFβ signalling. Disruption of this balance, by inhibition of the canonical pathway, induces HCC proliferation through TLR signalling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsCarcinoma, HepatocellularCytostatic AgentsLiver NeoplasmsAnimalsHumansMiceCell ProliferationMyeloid Differentiation Factor 88Proliferating Cell Nuclear AntigenTNF Receptor-Associated Factor 6Toll-Like ReceptorsTransforming Growth Factor betaReceptor, Transforming Growth Factor-beta Type I

Stichwörter der Autor:innen

HCCTGFβ signallingTGFβR1TRAF6toll-like receptors

Substanzen

Antineoplastic AgentsCytostatic AgentsMyeloid Differentiation Factor 88Proliferating Cell Nuclear AntigenTNF Receptor-Associated Factor 6Toll-Like ReceptorsTransforming Growth Factor betaTgfbr1 protein, mouseReceptor, Transforming Growth Factor-beta Type ITGFBR1 protein, human

Autor:innen und Institutionen

  • Department of Pathology, Faculty of Medicine, Minia University, Minia, Egypt.
  • Molecular Hepatology Section, Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
  • Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
  • Department of Medicine II, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Mannheim Institute for Innate Immunoscience (MI3), University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

ORCID-Profile: Fatma El Zahraa Ammar Mohamed

Förderung

  • German Federal Ministry of Education and Research
  • Alexander von Humboldt-Stiftung

Zitieren

APA

Mohamed, F. E. Z. A., Dewidar, B., Lin, T., Ebert, M. P., Dooley, S., Meindl-Beinker, N. M., & Hammad, S. (2024). TGFβR1 inhibition drives hepatocellular carcinoma proliferation through induction of toll‐like‐receptor signalling. International Journal of Experimental Pathology. https://doi.org/10.1111/iep.12501

Vancouver

Mohamed FEZA, Dewidar B, Lin T, Ebert MP, Dooley S, Meindl-Beinker NM, et al. TGFβR1 inhibition drives hepatocellular carcinoma proliferation through induction of toll‐like‐receptor signalling. International Journal of Experimental Pathology. 2024. doi:10.1111/iep.12501

BibTeX
@article{Mohamed2024,
  author = {Mohamed, Fatma El Zahraa Ammar and Dewidar, Bedair and Lin, Tao and Ebert, Matthias P and Dooley, Steven and Meindl-Beinker, Nadja M and Hammad, Seddik},
  title = {TGFβR1 inhibition drives hepatocellular carcinoma proliferation through induction of toll‐like‐receptor signalling},
  journal = {International Journal of Experimental Pathology},
  year = {2024},
  doi = {10.1111/iep.12501}
}
Kostenlos starten →